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Abstract Translational research is changing the practice of modern medicine and the way in which health 
problems are approached and solved. The use of small-animal models in basic and preclinical sciences is a 
major keystone for these kinds of research and development strategies, representing a bridge between 
discoveries at the molecular level and clinical implementation in diagnostics and/or therapeutics. The 
development of high-resolution in vivo imaging technologies provides a unique opportunity for studying 
disease in real time, in a quantitative way, at the molecular level, along with the ability to repeatedly and non-
invasively monitor disease progression or response to treatment. The greatest advantages of preclinical 
imaging techniques include the reduction of biological variability and the opportunity to acquire, in
continuity, an impressive amount of unique information (without interfering with the biological process under 
study) in distinct forms, repeated or modulated as needed, along with the substantial reduction in the number of 
animals required for a particular study, fully complying with 3R (Replacement, Reduction and Refinement) 
policies. The most suitable modalities for small-animal in vivo imaging applications are based on nuclear 
medicine techniques (essentially, positron emission tomography [PET] and single photon emission computed 
tomography [SPECT]), optical imaging (OI), computed tomography (CT), magnetic reso-nance imaging 
(MRI), magnetic resonance spectroscopy imaging (MRSI), and ultrasound. Each modality has intrinsic 
advantages and limitations. More recently, aiming to over-come the inherent limitations of each imaging 
modality, multimodality devices designed to provide complementary information upon the pathophysiological 
process under study have gained popularity. The combination of high-resolution modalities, like micro-CT or 
micro-MRI, with highly sensi-tive techniques providing functional information, such as micro-PET or micro-
SPECT, will continue to broaden the horizons of research in such key areas as infection, oncology, cardiology, 
and neurology, contributing not only to the understanding of the underlying mechanisms of disease, but also 
providing efficient and unique tools for evaluating new chemical entities and candidate drugs. The added value 
of small-animal imaging techniques has driven their increasing use by pharmaceutical companies, contract 
research organi-zations, and research institutions.
approached and solved. Its implementation is the basis for
real science-based medicine (‘from the researcher’s bench
to the patient’s bedside’), being hailed as ‘the’ right
direction for a more sustainable future, since it benefits
from multidisciplinary, multiphase, and multisectorial
projects to achieve solutions for health-related problems
[1]. Nowadays, the use of small-animal models in basic
and preclinical sciences is considered a major keystone
for research and development strategies in biosciences
[2]. It represents a bridge between discoveries at the
molecular level and clinical implementation in diagnostics
or therapeutics. This is of crucial importance for several
reasons: on one hand, knowing the role of a molecule in a
disease model in vitro may not mean that its role and
molecular interactions in vivo are fully understood, while,
on the other hand, human experimentation is not possible
in most cases due to ethical and logistical issues [3].
Simultaneously, increasing efforts in the development of
high-resolution in vivo imaging technologies are also
providing unique opportunities to study disease non-
invasively and, in many cases, quantitatively, at the
molecular level, along with the ability to repeatedly and
non-invasively monitor disease progression or response to
treatment [4]. The combination of basic science knowl-
edge and the new and more advanced animal models of
disease with highly developed imaging tools enables the
shortening of project length, improving the level of con-
fidence in the obtained results and revenues and cost
effectiveness. Moreover, the preclinical validation of drug
targeting is driving the use of small-animal in vivo
imaging technologies in drug development [3, 5]. Small-
animal imaging is being used in a wide variety of lines of
research, especially in infection, inflammation, oncology,
cardiology, and neurosciences.
In oncology, non-invasive in vivo imaging of tumors can
be valuable in evaluating a number of parameters, includ-
ing primary tumor mass/volume [6], number and location
of metastases [4, 7, 8], glucose metabolism [9], tumor cell
proliferation [10], gene expression [11–13], expression of
membrane antigens [14], tumor angiogenesis [15–17],
hypoxia [18], and apoptosis [19, 20].
Cardiovascular imaging is one of the most promising
applications of molecular imaging, allowing the early
detection of disease, risk stratification, monitoring the
outcomes of innovative therapies [21, 22], and character-
ization of atherosclerotic plaques [23–26].
Imaging the brain in small animals remains one of the
most challenging applications due to the small size of brain
structures, the complex kinetics, and the relatively low
tracer uptake [27]. However, cerebral blood flow, glucose
uptake, density of neurotransmitter receptors and trans-
porters, and drug occupancy studies have been successfully
measured [28].
This paper undertakes a concise and critical review of
the currently available modalities and emerging imaging
technologies for in vivo small-animal imaging. Further-
more, the contribution and relative importance of each
modality, including its advantages and limitations, is out-
lined. Finally, some considerations related to animal
imaging facilities, including main concept design and
workflow, is briefly covered. Examples of applications in
the neuroscience field are mentioned, to better illustrate
some of the ideas argued throughout the text.
2 Small-Animal Imaging Modalities
Zanzonico has provided a good definition of small-animal
or preclinical imaging, stating that ‘‘it constitutes a way of
assessing biological structures and function in vivo by non-
invasive means, allowing the collection of quantitative
information, both in health and disease states’’ [29]. That
these techniques are non-invasive renders longitudinal
studies possible, making it feasible to screen the entire
spectrum of disease process, from disease onset to pro-
gression and therapy monitoring. The greatest advantages
of imaging techniques are the reduction of biological var-
iability (each animal works as its own control), paralleled
by the substantial reduction in the number of animals
required for a particular study [29] (Fig. 1). Moreover, the
study of complex interactions between the physiological/
biochemical processes that occur in biological systems is
only possible with intact animals in which variables related
to immunological, nutritional, or hormonal aspects are
present, as well as systemic responses, which it is not
possible to fully evaluate with cell- or tissue culture-based
methods or in ex vivo systems. In fact, other more com-
plex, invasive, or time-consuming procedures, such as
dissection, fixation, and sectioning, might be avoided [30].
As most small-animal imaging techniques are the same as
those used in the clinical setting, results are easily trans-
latable to humans [29, 31].
However, many challenges are still to be overcome
when imaging a 20- to 30-g mouse as compared with a
70-kg human, such as the size of the subject, the total
volume to be imaged, the spatial resolution needed to
obtain adequate anatomical and/or functional data as well
as the total time spent acquiring a set of images [31]. The
major challenge is to obtain a signal-to-noise ratio as high
as possible and to localize the imaging probe as precisely
as possible, while maintaining a good temporal resolution,
using the minimum amount of molecular probe [32].
Among the different imaging modalities, nuclear medi-
cine-based techniques (positron emission tomography
[PET] and single photon emission computed tomography
[SPECT]), optical imaging (OI), computed tomography
1 Introduction
Translational research is changing the practice of modern
medicine and the way in which health problems are
(CT), magnetic resonance imaging (MRI), magnetic reso-
nance spectroscopy imaging (MRSI), and ultrasound are
the most suitable for non-invasive in vivo imaging, with
the use of important pillars such as genomics, proteomics,
and nanotechnologies [33].
Before dedicated devices were commercially available,
small-animal imaging was performed in clinical instru-
mentation. Although the acquired images lacked proper
resolution and sensitivity, it represented the first steps,
which were not only an important contribution to demon-
strating the valuable information that could be obtained
from these techniques but was also the crucial impulse for
the development of specific instrumentation that fulfill the
need for improved equipment performance (namely, better
spatial resolution, sensitivity, and tissue contrast). These
improvements were related to imaging software and hard-
ware (such as stronger magnetic fields and improved gra-
dient fields and coils in MRI, reduction of ring diameter
and detector-element size in PET, development of special
pinhole collimators and multi-pinhole acquisition in
SPECT, increase of X-ray flux and reduction of the focal
spot in CT, and increase in ultrasound frequency) [29].
The existing imaging technologies differ essentially in
their physical basis and in the type of information supplied
(Table 1). Of critical importance are parameters such as
spatial and temporal resolution, penetration depth, energy
needed for image generation (ionizing or non-ionizing
radiation), availability of molecular probes, and the
respective detection threshold [32, 34].
2.1 Micro-SPECT
SPECT and PET techniques are based on the tracer prin-
ciple laid down by the Hungarian Nobel Laureate, George
von Hevesy, which involves the injection of tiny amounts
of radioactive tracers and the external assessment of their
biodistribution by appropriate detectors. SPECT is able to
detect \10-10 molar of tracer molecules in vivo with sub-
millimeter (0.5–0.7 mm) resolution, allowing the quantifi-
cation of the molecular processes in which radioactive
tracers are involved [35].
The use of multi-pinhole collimation has become the
standard in most preclinical SPECT systems, resulting in
great improvements, not only in spatial resolution but also
in system sensitivity [36]. Sensitivity can be improved by
increasing the number of pinholes and/or the angular
sampling for a fixed field of view (FOV) [30, 37]. How-
ever, the overlapping projections from the distinct pinholes
may constitute the main limitation in multi-pinhole colli-
mator design, as the ‘multi-plexing’ phenomenon occurs,
creating uncertainty about which pinhole a certain photon
may have passed through. Therefore, the sensitivity
advantage might be mitigated by the added pinholes and
reconstruction artifacts may eventually arise [36]. Conse-
quently, the use of a high-sensitivity, non-multiplexing,
multi-pinhole approach might be considered a step
forward.
Improvements in several system components have also
been introduced, namely, new crystal materials in
Fig. 1 Comparison between the number of animals used in tradi-
tional approaches and in small-animal imaging approaches. The
traditional approach requires that a group of animals be sacrificed at
each time point, making it impossible to study a single animal serially
over time, and necessitating the use of a drastically greater number of
animals to obtain statistical significance. The greater the number of
time points required for a certain study, the greater the number of
animals to be used, in practice limiting the number of time points to
be studied. Conversely, when using small-animal imaging techniques,
the same group of animals is studied over the entire length of the
study, significantly reducing the total number of animals to be used,
without compromising the statistical significance and adding the
possibility of having more time points, always without increasing the
number of animals. Moreover, traditional techniques are low
throughput and time consuming compared with small-animal imaging
techniques
detectors, including thallium-doped cesium iodide
[CsI(Tl)], sodium-doped cesium iodide [CsI(Na)], and
cerium-doped lanthanum bromide [LaBr3(Ce)], which offer
improved light output and energy resolution and position-
sensitive photomultiplier tubes (PMT). Finally, improve-
ments in electronics have not only enhanced sensitivity, but
also considerably reduced the overall equipment size and
cost [30, 36, 37]. Some preclinical SPECT systems incor-
porate semi-conductor materials, such as cadmium zinc
telluride (CZT) or silicon, as direct converters of gamma
rays to electric signals [3, 38]. These detectors offer
excellent spatial resolution, as low as 0.38 mm [39] and
energy resolution, particularly important for low-energy
radionuclides (as iodine-125) or dual isotope applications
[3].
Although the use of scintillation crystals coupled to
PMT is still very common, along with position estimation
based on Anger logic principles, recent years have evi-
denced hardware progress that has been the basis of a
drastic increase in available computational power. This has
allowed the introduction of more sophisticated algorithms
in data processing, essentially iterative algorithms, as the
maximum-likelihood estimation and resolution recovery
advanced solutions, thus improving global performance of
systems [36]. Table 2 summarizes the main features of
commercially available SPECT systems.
Single photon (SPECT) emitters are well suited for radio-
labeling a variety of molecules, including endogenous bio-
molecules, such as peptides, antibodies, hormones, and
selectins. These biomolecules are relatively large, making
their diffusion into tissues, and blood clearance, low. This
favors the use of radionuclides with longer half-lives (hours)
in order to broaden the temporal window of observation, in
contrast to positron emitters (with minutes of physical half-
life) [35]. In neurosciences, drug-occupancy studies are
often performed to evaluate the selectivity of a drug to
specific brain regions. Our group used 123I-iodobenzamide
(123I-IBZM) to evaluate dopamine receptor (D2R) occu-
pancy in C57BL/6J mice, before and after the administration
of a dopamine agonist drug that induces the displacement of
striatal 123I-IBZM binding, resulting in a decreased specific
uptake ratio in the striatum (Fig. 2).
2.2 Micro-PET
PET is a well established clinical and preclinical imaging
technology based on the application of compounds labeled
with positron-emitting radioisotopes to image and measure
several biochemical and physiological processes [40]. Due
to its molecular, non-invasive, and non-destructive intrinsic
nature, combined with the ability to study many bio-
chemical/biological processes in vivo, it is universally
recognized as a fundamental tool for biomedical research
[41]. The possible fields of application for PET are quite
broad, ranging from oncology to neurology and cardiology,
among others, with less expression, but yet very relevant
for infection and inflammation imaging.
The most commonly used positron emitters are 11C, 13N,
15O, and 18F, but other isotopes such as 60,61,64Cu, 68Ga,
76Br, 94mTc, 89Zr, or 124I are gaining increasing attention
and/or being tested for clinical applications. In fact, pep-
tides labeled with 68Ga have already demonstrated very
promising results in the assessment of neuroendocrine
tumors [42]. 89Zr is well suited for the labeling of mono-
clonal antibodies, since more time for optimal biodistri-
bution and tumor targeting is usually required [43].
Similarly, 124I has demonstrated higher efficacy in lesion
detection and the ability to provide lesion-specific dosim-
etry in the context of differentiated thyroid cancer [44].
Although these radionuclides allow the study of many
physiological and biochemical processes, they are difficult
to obtain for many research groups, given their production
method (mainly cyclotron-based) and the relative com-
plexity and low yield quite often inherent to most of those
‘non-traditional’ (so ‘non-optimized’) synthesis processes.
Additionally, their relatively short physical half-life makes
distribution over long distances impractical or very
expensive [45]. Even greater development in the
Table 1 Summary of general properties of diagnostic imaging modalities
Imaging modality Physical basis Information supplied Clinical use
Positron emission tomography (PET) Gamma-radiation (derived from
positron emission)
Tracer uptake Yes
Single photon emission computed
tomography (SPECT)
Gamma-radiation Tracer uptake Yes
Optical imaging (OI) Light emissions (ex: fluorescence) Probe uptake Yes (image-guided
surgery only)
Computed tomography (CT) X-rays Tissue density Yes
Magnetic resonance imaging (MRI) Magnetic properties Tissue composition Yes
Ultrasound (US) Sound reflection of high-frequency
sound waves
Internal movements and flows,
differences of tissues
Yes
production and availability of positron emitters is expected
in the near future. Not only due to the huge amount of work
by a large number of researchers developing their activities
in order to produce an increasing number of agents based
on the interesting biochemical and physical properties of
some of the above-mentioned radionuclides, but also to the
increasing number of fully equipped dedicated facilities,
radiopharmaceutical production and distribution centers,
essentially based on low-energy (the so-called ‘medical’)
cyclotrons and their specially dedicated laboratories. In
fact, due to the short physical half-lives of most positron
emitters (from seconds to a few hours), the use of this
imaging modality may require in situ radioisotope pro-
duction and compound labeling, and consequently, the
existence at close distance of a multidisciplinary highly
skilled and specialized team, with knowledge from distinct
scientific areas.
Figure 3 summarizes the main steps of a PET study,
where the agent has been produced either locally or
externally and then delivered to its destination of final use.
In fact, a huge number of radiotracers can only be used if
locally produced, so it is now considered ideal for a pre-
clinical facility (in order to adequately develop its role) to
be near a radiopharmaceutical production facility. This is
indeed a highly complex and costly condition; however,
recent advances in cyclotron technologies, namely the
anticipated introduction of the ‘tabletop cyclotrons’ and its
‘all-integrated and automatic radiochemistry’ approaches
(directly for an interesting number of radioisotopes, such as
11C, 15O, 13N, beyond the ‘classical’ 18F) might overcome
those aspects in the very near future.
An ideal PET scanner designed for small-animal imag-
ing would have the following characteristics: high spatial
resolution (sub-millimeter range), high sensitivity, detector
ring with a FOV optimized to the specific targeted animal
size range, good temporal resolution, and multimodality
imaging capability. Many commercially available micro-
PET scanners have resulted from previously developed
prototypes in academia [46, 47]. Nowadays, the main
players are either companies specializing in the preclinical
field or big companies known in the clinical imaging arena
that also present preclinical imaging devices in their port-
folio. Table 3 presents some examples of the devices
available in the market and their respective features.
Micro-PET detector blocks are made of inorganic
scintillators, such as lutetium oxyorthosilicate (LSO),
lutetium-yttrium oxyorthosilicate (LYSO), or gadolinium
orthosilicate (GSO), which have replaced the old bismuth
Fig. 2 123I-I-iodobenzamide
uptake in mouse striatum
measured in single photon
emission computed tomography
– magnetic resonance imaging
(SPECT-MRI) co-registration
images. Transaxial section
planes of the mouse brain,
striatal uptake is high in the left
panel, while displacement is
imaged in the right panel with
low striatal uptake of the
dopamine transporter ligand
Table 2 Features of some commercially available micro-SPECT scanners
Manufacturer Equipment Detector Spatial
resolution (mm)
Best sensitivity value
(cpm/MBq)
Collimation (no. of
pinholes)
Multimodality
options
Source of
information
Bruker (ex-
carestream)
Albira CsI(Na) 0.6 1.000 9 PET and CT Company
website
Mediso NanoSPECT NaI(Tl) 0.66 [4.000 36 CT [113]
Mediso nanoScan
SPECT
NaI(Tl) 0.275 [10.000 100 CT or MRI Company
website
MILabs VECTor NaI(Tl) 0.38 [525 75 PET and/or CT [114]
Siemens Inveon NaI(Tl) 0.5 2118 1 PET and/or CT [115]
CsI(Na) sodium-doped cesium iodide crystal, CT computed tomography, CZT cadmium-zinc telluride solid state detector, MRI magnetic
resonance imaging, NaI(Tl) thallium-doped sodium iodide crystal, PET positron emission tomography, SPECT single photon emission computed
tomography
germanate (BGO) scintillators with their more favorable
speed, light output, and detection efficiency [46, 48]. In
comparison with clinical scanners, micro-PET devices
provide much better sensitivity and spatial resolution.
These scanners can achieve spatial resolution values of
around 1.0 mm in reconstructed images, but only conju-
gating the application of radioisotopes with low energy
positrons (from 18F, for instance) with a state of the art
equipment that could reach pixel size less than 1.2 mm and
an intrinsic resolution of 0.7 mm [49]. In fact, the positron
range, depending on positron energy, is a hard physical
intrinsic barrier to PET resolution (thereby SPECT will
always have higher resolution, due to the lack of anything
similar to the ‘positron range’ in gamma-emitting
isotopes).
Over the years, PET has been established as a powerful
and reliable tool in the biomedical research arena. Yet, its
utilization (concerning both the quantity and the diversity
of available procedures) is highly dependent on the pre-
sence or not of an ‘on site solution’ for radiopharmaceu-
tical production, since without it, PET imaging will be
entirely dependent on the existence of a reliable radiotracer
distribution network of fluorinated compounds, those
which are the most easily and currently distributed. This is
why one of the most useful and widely used parameters is
glucose consumption in a variety of situations, for exam-
ple, by a tumor or by brain tissue. Figure 4 exemplifies the
use of 18F-FDG, a known glucose analog, for the assess-
ment of mouse brain glucose uptake under control condi-
tions and after drug preconditioning that induces a massive
increase in glucose uptake by all regions.
Even considering these relevant potential limitations,
the application of this imaging modality has been
increasing considerably in industrialized countries, and is
Fig. 3 Main steps of a positron
emission tomography (PET)
study using a locally produced
agent (upper row) compared
with an externally produced and
locally distributed agent (bottom
row)
Table 3 Features of some commercially available micro-PET scanners
Manufacturer Equipment Crystal Transaxial
FOV (cm)
Spatial resolution
(mm)
Sensitivity
(%)
Multimodality
options
Source of
information
Bruker Albira LYSO 8 1.3 3–9 SPECT and/or
CT
[133]
Mediso nanoScan
PM PET
LYSO 12.4 0.7 9 CT or MRI [134]
MILabs VECTora NaI(Tl) crystals 8.2 0.75 (Variable) SPECT and/or
CT
[135]
Raytest ClearPET LYSO and LuYAP in
double layer
11 1.5 5 CT or MRI [136]
Siemens Inveon LSO 12.7 1.4 10 CT and/or
SPECT
[137]
Sofie
biosciences
Genisys4 BGO 4.5 1.4 14 X-Ray [138]
BGO bismuth germanate, CT computed tomography, FOV field of view, LGSO lutetium-gadolinium oxyorthosilicate, LSO lutetium oxyorth-
osilicate, LuYAP cesium doped lutetium-yttrium orthoaluminate, LYSO lutetium-yttrium oxyorthosilicate, MRI magnetic resonance imaging,
SPECT single photon emission computed tomography
a Due to special collimator design, VECTor might be seen as a high-energy collimated SPECT
now ranked as the third most used single preclinical
imaging technique, representing 20 % of the preclinical
imaging applications, just behind OI (with 28 % only for
the bioluminescence techniques) and MRI, with 23 % [50].
2.3 Micro-SPECT versus Micro-PET
One of the major strengths of nuclear imaging techniques is
the ability to image the same animal using a variety of
tracers with different biological characteristics, providing
information about the molecular affinity of the tracer for
the distinct biological processes being studied.
Traditionally, PET imaging has been seen as the more
accurate for quantification purposes due to its higher sen-
sitivity. However, in recent years, development of SPECT
systems has led to higher resolution and sensitivity capa-
bilities, making it a very attractive option for quantitative
in vivo imaging [51]. The leading advantages of PET
include its higher detection efficiency and, when it is the
case, the availability of such positron-emitting radionuc-
lides as 11C, 13N, 15O, and 18F, which allows the labeling of
many physiologically and biochemically interesting bio-
markers that are involved in health and disease processes
[52–54].
The most important hardware difference between PET
and SPECT cameras is normally the absence of a
collimator in PET, making it about tenfold more sensitive,
as collimators reject many of the counts arising from the
source [55]. However, PET has intrinsic limitations asso-
ciated with positron range (0.6–3 mm), non-collinearity of
photons, and random events that limit the spatial resolution
of the system [27, 30, 56, 57]. This is why current small-
animal PET systems have a standardized spatial resolution
of 1.55 mm (range of 1–2.2 mm) [4, 58], while typical
SPECT systems offer improved resolution in the order of
0.35–0.7 mm [35, 59, 60].
The major advantages of SPECT are the ability to use a
variety of radioactive agents based on radioisotopes with
different energies, a relatively simple and stable chemistry
allowing the synthesis of ligands on site, and their rela-
tively long physical half-life, making them easily accessi-
ble for many research groups [35, 45] and suitable for use
in investigational contexts where there is a need for longer
periods for data acquisition (see Tables 4 and 5 to compare
the most widely used PET and SPECT agents). Many of the
SPECT agents can be obtained from central radiopharma-
cies, as they are widely used in clinical nuclear medicine.
In many cases, if a desired radiopharmaceutical is not
commercially available, a relatively simple laboratory
setup is enough to produce it. Another advantage of small-
animal SPECT is its ability to image multiple radiotracers
that emit different energy photons simultaneously,
Fig. 4 Increased 18F-Fluoro-
Deoxy-D-Glucose uptake in the
mouse brain after drug
treatment (bottom row)
compared with normal glucose
uptake in a non-treated mouse
(upper row). PET/MRI
(nanoScan PM, Mediso,
Hungary) images acquired
under light isoflurane
anesthesia. Coronal (left) and
transverse slices (right) are
shown. A anterior, Cer
cerebellum, Ct brain cortex,
F feet direction, H harderian
glands, L left, MRI magnetic
resonance imaging, P posterior;
PET positron emission
tomography, R right, Th
thalamus
providing information from distinct biological processes at
the same time, from the same model [53]. Finally, small-
animal SPECT studies generally cost less than other
imaging methods, such as small-animal PET [3].
The mass effect of the injected dose is a very important,
although often neglected, aspect of imaging small animals
with radionuclides. In general, the amount of injected
radioactivity does not scale with the animal size. When
going from human to mouse, the volume resolution ele-
ment is reduced from about 1 cm to 1 mm. However,
compared with clinical applications, spatial resolution
requirements in small-animal imaging are much higher; the
concentration of the injected tracer per gram of tissue is
usually much higher in small animals, with a ratio of 20
times that in a human [47, 61]. Moreover, in order to obtain
a comparable number of counts per pixel, and thus a global
spatial resolution between clinical and preclinical scanners,
significantly higher doses of radioactivity per unit of body
mass should be administered for imaging rodents in pre-
clinical scanners. Accordingly, this leads to the adminis-
tration of a higher amount of chemical compound per body
mass, which may threaten the validity of the tracer prin-
ciple (so implicating the occupancy of \5 % of the total
available receptor sites) [62]. Another important constraint
in small-animal imaging is the maximum injected volume,
which should not exceed 10 % of the total blood volume.
Therefore, when considering a 20-g mouse with a blood
volume of 2 mL, intravenous injections should ideally not
exceed 200 lL [63]. Considering all this, in order to obtain
accurate and reproducible results, it is crucial that radio-
active tracers have high specific activities, which is con-
siderably more achievable with SPECT than with PET
tracers [63] (Tables 4, 5).
Acquiring high-quality images of the mouse brain can
be very challenging due to the low radiotracer uptake
(typically below 1 % of the administered activity) and to
the small sizes of the structures to be imaged. Despite the
high sensitivity of PET, SPECT has a clear added value in
brain applications due to the higher spatial resolution
(below 1.0 mm) and the afore-mentioned ability to use
longer-lasting radionuclides (Tables 2, 3, 4, and 5).
Moreover, PET tracers usually have much lower specific
activities than SPECT-labeled compounds, which may lead
to significant receptor occupancy or eventually to phar-
macological effects [3].
Although small-animal SPECT and PET images offer
unique functional information at the molecular level, they
are often difficult to interpret because of the lack of
Table 4 Main characteristics of the most used SPECT radionuclides
Radionuclide Decay mode Physical half-life Photon energies—keV and abundances (%) Specific activity (GBq/mol)
99mTc Isomeric transition 6.02 hours 140 (89) 2.0–5.0 9 109
67Ga Electron capture 3.26 days 93 (36); 184 (20); 296 (16) 1.3–2.7 9 106
123I Electron capture 13.2 hours 159 (83) 12.3 9 107–43 9 108
131I Beta minus 8.02 days 284 (6); 364 (81); 637 (7) 222–327 9 106
111In Electron capture 2.80 days 173 (90); 245 (94) 60 9 106
201Tl Electron capture 3.04 days 69 (27); 71 (46); 80 (20) 8.0 9 105–8.0 9 106
Table 5 Main characteristics of the most used PET radionuclides
Radionuclide b? Decay
(%)
Physical half-life
(minutes)
Max positron energy
(MeV)
Mean positron range in
water (mm)
Production Specific activity
(GBq/mol)
11C 99 20.4 0.98 1.12 Cyclotron 3.4 9 105
13N 99 10.0 1.19 1.44 Cyclotron 6.8 9 105
15O 100 2.07 1.72 2.22 Cyclotron 3.4 9 106
18F 97 109.8 0.63 0.64 Cyclotron 6.3 x 104
68Ga 90 68.3 1.90 2.24 Generator n.a.
82Rb 96 1.3 3.15 2.80 Generator n.a.
89Zr 22,3 4708.8 8.97 1.18 Cyclotron 1.8–44.2 9 106
124I 25 6048 3.16 2.80 Cyclotron 1.11 9 109*
* Data from Veit-Haibach et al. [121]
n.a. information not available, PET positron emission tomography
correlation with anatomic structures or biologic landmarks.
This lack of detailed anatomical information may be con-
sidered the major weakness of nuclear techniques, some-
times making it difficult to clarify the precise localization
of tracer uptake and the delineation of regions of interest
for quantitative analysis. This is an important issue, since
the accuracy of quantitative analysis is dependent on a
variety of factors, namely, the real size of the lesion/region,
the intensity of tracer uptake, the image contrast, the
attenuation of the gamma rays by the surrounding tissues or
the scanner materials, the color scale, and the image
intensity threshold (upper and lower limits) [64].
2.4 Micro-CT
Micro-CT is a morphological imaging technique that
measures and compares differences in tissue densities. It is
conducted at an almost microscopic level compared with a
clinical CT system used for human imaging [65]. A typical
micro-CT system consists of an X-ray tube and an X-ray
detector assembled in opposing positions in a rotating
gantry. Although the underlying physical principles of both
preclinical and clinical scanners are the same, the former
requires images with higher resolution. In this sense, spe-
cial components had to be introduced, such as X-ray tubes
with smaller focal spots and detectors with small elements,
to produce sharp images. Micro-CT provides 3-dimen-
sional (3D) tomographic data at microscopic spatial reso-
lution (50 lm) and sub-second temporal resolution (50 ms)
[66] of soft tissues and bone structures by capturing hun-
dreds of 2-dimensional (2D) projections from multiple
angles around the animal [30, 54, 65, 67]. This imaging
modality has been useful in a number of applications,
namely the assessment of skeletal and lung abnormalities,
heart function, and tumor growth. Micro-CT is a robust
technique for the quantitative evaluation of angiogenesis
associated with solid tumors or ischemia [30, 67]. Although
CT is the preferred technique for lung imaging, due to the
high contrast provided by air/tissue differences, in the
preclinical context, imaging of such small and moving
structures has been challenging [67]. To overcome this
problem, respiratory gating devices have become com-
mercially available over recent years, thus reducing
breathing motion-related artifacts [54]. This has resulted in
increased lung tissue image contrast, thus significantly
improving image quality [65].
CT is entirely based on the quantification of X-ray
attenuation by the tissues, meaning that subtle differences
are very difficult to distinguish due to almost identical
attenuation characteristics. In an attempt to overcome this
limitation, contrast agents might be administered, enhanc-
ing CT sensitivity by highlighting either the vascular tree
or specific areas of organs or tissues. The most commonly
used CT contrast agents are iodinated water-soluble com-
pounds, usually administered by intravenous injection [68].
These agents distribute exclusively in the extracellular fluid
space and present very short biological half-lives due to
fast clearance, which shortens the temporal window of
observation and consequently, prevents their wider utili-
zation [69]. The main advantages of micro-CT over other
small-animal imaging modalities are the high spatial res-
olution images, with detailed morphological information
and the time required for scanning (typically 10–15 min).
Nevertheless, the radiation burden associated with CT
imaging, and the volume of contrast agents (used to
enhance the contrast resolution) that it is possible to inject
into a single animal (particularly mice), are potential lim-
itations of which researchers should be aware. Generally,
depending on the desired image contrast and resolution,
modern scanners provide short acquisition times with res-
olution levels below 100 lm and radiation doses in the
range of 10–50 mGy [70]. Researchers should always be
aware that, as in the clinical context, a balance between
image quality and animal irradiation must be found in order
to meet As Low As Reasonably Achievable (ALARA)
principles, thus avoiding unnecessary radiation exposure,
which is particularly important when imaging series are
required.
2.5 Micro-MRI
MRI is a non-ionizing 3D imaging technique that uses
magnetic properties of tissues and their interactions with
strong external magnetic fields. Due to its paramagnetic
properties as well as its ubiquitous body distribution,
hydrogen nucleus (1H) from water molecules is most used
in MRI imaging. Briefly, the underlying principle is that,
when a sample within a magnetic field is subjected to a
radio-frequency pulse, its protons absorb energy and gen-
erate a detectable signal during the relaxation phase that
can be digitally encoded through magnetic field gradients
to generate digital images. The strength of the signal is a
function of the number of protons, and the differences in
the microenvironment of those protons between tissues
determine the appearance of the image [2, 5, 71, 72]. Water
has a wide variety of biophysical magnetic signatures in
tissues and organs, and a key to success in many experi-
ments is optimizing experimental methods and parameters
in order to enhance contrast between healthy and patho-
logical tissue [2].
Micro-MRI provides morphological images with excel-
lent contrast and spatial resolution (100 lm), as well as
information regarding tissue composition, perfusion, oxy-
genation, tissue elasticity, metabolism, and detection of
molecular probes, within a single acquisition session
without radiation exposure [73]. These attributes have
contributed to the increasing popularity of MRI among
scientists and hence the widespread utilization. Nowadays,
this imaging modality represents about 23 % of all small-
animal imaging procedures [50]. Compared with clinical
scanners, preclinical MRI scanners require a tenfold
increase in spatial resolution in each dimension (X, Y, Z),
resulting in signal reductions of at least 1,000. To over-
come this challenge, stronger magnets, specific receiver
coils and radiofrequency receiver chains, and stronger
gradient sets were introduced [74]. As the signal-to-noise
ratio increases with the magnetic field, small-animal MRI
scanners should be at least 4.7 T or, ideally, higher than
7.0 T, according some authors. In fact, dedicated small-
bore MR devices can operate between 4.7 and 21 T.
However, they are very expensive and not widely avail-
able. Moreover, one should be aware that 1.0 T represents
20,000 times the magnetic field of the planet (so, 140,000
times for the above-mentioned 7.0 T devices) and even
though, to our knowledge, there is no consistent evidence
of physiological alterations induced by (extremely) high
magnetic fields, such hypotheses should never be dis-
carded, in our opinion.
If requirements concerning spatial and temporal reso-
lution are not particularly strict, clinical scanners (operat-
ing typically between 1.5 and 3.0 T) may be a suitable
option as long as special radiofrequency coils and opti-
mized pulse sequences are used [74, 75].
Currently, a variety of MRI techniques are available for
the study of many biological processes. One example is
diffusion-weighted imaging (DWI), based on Brownian
motion, allowing the characterization of the movement of
protons in tissues, mainly from the water molecule during
an interval of time. Molecular diffusion in tissues is the
result of the interaction of molecules with many ‘barriers’
such as other molecules, cellular organelles, fibers, and
membranes. The molecular diffusion patterns provide
information about tissue architecture and cellularity, since
the higher the cell density (more barriers), the lower the
diffusion will be, leading to high signal intensities in dif-
fusion-weighted images and to low ‘apparent diffusion
coefficient’ (ADC) values [76]. DWI has been used for
tumor characterization in non-moving structures such as
bones and the brain [77], being particularly sensitive for
the early detection of brain ischemia [78].
Another MRI technique is the so-called ‘functional
MRI’ (fMRI; also designated by blood oxygen level
dependent [BOLD]), based on the conjunction of both
neuronal activity and brain hemodynamics. fMRI essen-
tially measures changes in blood oxygenation, which
translate into changes in the magnetic field. This is possible
because oxyhemoglobin and deoxyhemoglobin have dis-
tinct magnetic properties (the former is weakly diamag-
netic, while the latter is paramagnetic), inducing
inhomogeneities into the surrounding magnetic field. Thus,
a decrease in the concentration of deoxyhemoglobin will
increase image intensity. This technique is commonly used
for brain activation studies [79].
Perfusion measurements are possible using two distinct
MRI techniques: (i) the dynamic contrast-enhanced imag-
ing (DCE–MRI), in which an intravenous bolus injection of
a contrast agent is detected during its first passage through
the organs and (ii) arterial spin labeling (ASL), in which
the arterial blood water magnetization itself functions as an
endogenous contrast agent [76]. The size of the contrast
agent in DCE–MRI will determine its washout from the
vascular space, making it possible to measure vascular
permeability [76]. The ASL technique works better at high
magnetic fields (3.0 T and above) and highly irrigated
organs, such as the brain, the heart, muscles, and kidneys,
with the advantage of not requiring contrast injection,
allowing repeated measurements [76, 80–83].
MRI is now a well established modality for imaging the
cardiovascular system, providing valuable information
concerning structure, function, and perfusion, both at cel-
lular and at molecular levels in mouse models of cardio-
vascular disease. It is also a powerful modality for the
determination of the cardiovascular phenotypes of geneti-
cally engineered mice and the evaluation of novel targeted
contrast agents (e.g. gadolinium, manganese, and super
paramagnetic iron oxide nanoparticles [SPION]) [53, 54].
In oncology, MRI has been used extensively in the
characterization of tumors in a wide variety of animal
models, namely tumor growth and development. Due to its
sensitivity to dynamic processes, it is an excellent tool to
image tumor perfusion/angiogenesis and oxygenation.
Moreover, the non-invasive and non-destructive nature of
MRI is particularly advantageous in monitoring in vivo
tumor growth and ablation in response to therapy, as it is
possible to serially monitor individual subjects of a given
cohort over an extended period of time [2, 71]. Micro-MRI
has also been successfully applied in the assessment of
musculoskeletal tissue structures such as tendons, cartilage,
menisci, and ligaments (although the assessment of bone
structure remains a challenge because only 15 % of the
bone volume is composed of water) [72].
2.6 MRSI
MRSI is a combination of magnetic resonance spectros-
copy (MRS) and MRI, wherein the first modality provides
physiological/biochemical information and the latter ana-
tomical information. In reality, MRSI imaging consists of a
hybrid system that provides and relates images in a given
tissue or organ with the concentration of certain chemicals
found in the same tissue or organ, providing information
about tissue biochemistry. These chemicals are detectable
by the MR process because they are composed of nuclei
that have a magnetic moment (such as hydrogen [1H],
carbon [13C], phosphorus [31P], and fluorine [19F]) [84].
Magnetic nuclei in a molecule are surrounded by other
magnetic or charged particles with which they interact,
causing a chemical shift, providing unique resonance fre-
quencies for nuclei of different molecular groups. In fact,
resonance frequencies of nuclear spins depend on their
chemical environment, providing a resonance signature of
the chemical structure, allowing the identification of the
compounds present in the organ being studied [85]. The
intensity of the spectral signals is related to the concen-
tration of the compound in tissues, thus allowing quanti-
tative approaches. In order to achieve a high signal-to-noise
ratio, high magnetic fields are required (3.0 T and above)
[86].
MRSI has had an established role as a clinical tool since
it was approved by the US FDA in 1995 [87], allowing the
detection of relatively small-sized molecules, usually in
concentrations of 0.5–10 mM [88]. Similarly to MRI,
hydrogen-based MRS, which is also called ‘proton MRS’,
has become increasingly popular due to the high natural
abundance of protons, their high absolute sensitivity to
magnetic manipulation, better spatial resolution [87]
(compared with MRS based on other, less abundant, nuclei
such as 13C or 19F), and relatively simple technique (that
can be performed using clinical MRI systems with standard
radiofrequency coils), as well as the abundant presence of
these nuclei in most metabolites [87, 88]. The results of
MRS are displayed as a spectrum, where the concentration
of a metabolite is linearly proportional to its spectral peak
area [89]. Although MRS can theoretically be performed in
almost any tissue of the human/animal body, the brain has
been the main target of MRS studies [87, 90], with
N-acetyl aspartate, choline, creatine, myo-inositol, lactate,
lipids, glutamine, glutamate, and amino acids being the
major compounds of interest [87, 89]. It has also been
shown to be useful in the assessment of tumor metabolism
in breast, brain, and prostate cancers. This modality can
detect specific genetic and metabolic changes that occur in
malignant tumors, being able to define different metabolic
tumor phenotypes [91].
2.7 Micro-CT versus Micro-MRI
To conduct a legitimate comparison between preclinical
CT and MRI, it is essential to understand that, despite both
of these techniques providing mainly anatomical informa-
tion, they have entirely distinctive applications and
underlying principles. In fact, both of the techniques go far
beyond the anatomical information they initially provided,
autonomously evolving at not only an individual level, but
also as a component of hybrid imaging techniques such as
PET-CT and PET-MRI. Generally, X-ray-based methods
are less expensive and time consuming than MRI. Micro-
CT provides excellent contrast and spatial resolution of
bone structures and MRI is more suitable for soft-tissue
assessment due to its higher sensitivity and contrast, pro-
viding important information regarding the biological
properties of tissues. The spatial resolution of micro-CT is
better (50 lm) than micro-MRI (100 lm). Moreover, MRI
does not involve ionizing radiation, which is often con-
sidered advantageous for longitudinal studies. MRI is also
a very effective imaging method when it comes to read-
outs from a single scanning session, as many different
facets of MRI-acquired data analysis and reconstruction
exist. In fact, in its multiple facets, MRI is able to provide
not only detailed anatomical information but also unique
physiological data such as organ perfusion, blood velocity,
blood volume, vessel permeability, molecule diffusion,
oxygen consumption, and tissue chemical composition
[76].
2.8 Optical Imaging
OI includes a variety of techniques that have in common
the use of a set of light sources and respective sensing
devices to capture the resulting photon distribution. These
techniques can be classified according to the type of
source-detector setting and the contrast mechanism
applied. To improve image contrast, targeted fluorescent
or activatable probes were developed, making it possible
to measure the activity of the chosen molecular targets.
Imaging of such probes involves the excitation of the
probe at a certain wavelength and the detection of the
specific signal emission at a significantly different
wavelength. The most relevant OI techniques are biolu-
minescence, fluorescence, and near-infrared (NIR) fluo-
rescence imaging [92]. Recent reports have also described
OI techniques being used to image ultraviolet and visible
light produced by radioactive materials—Cerenkov
imaging [93].
For image acquisition, the animal must be placed in a
light-tight imaging enclosure and the emitted light is then
captured by a charged-coupled detector (CCD). In order to
detect visible to near infra-red light emitted from the body,
highly sensitive detectors have been produced; CCD
detectors that are made of silicon crystals sliced into thin
portions for assembly into integrated circuits [32]. CCD
cameras operate by converting light photons at wave-
lengths between 400 and 1,000 nm, that strike a CCD pixel
with an energy of only 2–3 eV [32].
The principle of bioluminescence imaging consists in
the emission of visible photons at specific wavelengths
based on reactions catalyzed by enzymes (luciferases)
present in many organisms as protists, fungi, insects,
bacteria, among other species [94]. Luciferases catalyze the
oxidation of luciferins (substrate), creating non-reactive
oxyluciferins and releasing photons of light [95]. Over the
last decade, advances in molecular techniques have led to
the isolation of many luciferase genes that have been used
to build DNA vectors [94]. Currently, the most commonly
used varieties of luciferase–luciferin are the firefly (Fluc)
[95].
Highly sensitive imaging systems allow the quantitative
detection of small numbers of cells or organisms that
express luciferase as a transgene [31]. This technique
requires the target cells to have been previously genetically
transduced ex vivo in order to express the ‘reporter’ or
luciferase gene. The luciferase substrate (luciferin) is then
systemically administered and when it reaches the target
cells, is oxidized by luciferase, emitting photons that are
captured by CCD cameras [92].
A bioluminescence image is often shown as a color
image that is superimposed on a gray-scale photographic
image of the small animal using overlay and image analysis
software. The main advantage of optical bioluminescence
imaging is that it can be used to detect very low levels of
signal (as there is almost no background light).
The principle of fluorescence imaging is different from
that of bioluminescence. Here, an excitation light with a
wavelength in the visible range of 395–600 nm illuminates
the animal and a CCD camera captures an emission light of
shifted wavelength. Cells can be either genetically trans-
duced in order to express a fluorescence molecule as the
green fluorescent protein (GFP) or a fluorescent probe like
a fluorescence-labeled antibody may be systemically
administered [32]. In NIR fluorescence imaging, light in
the 700- to 900-nm range is used to maximize tissue pen-
etration and minimize autofluorescence from non-target
tissues [96].
Diffuse optical tomography (DOT), a computational
approach to OI, presents improved imaging performance as
multiple source-detector pairs are used to produce 3D
images with good sensitivity and spatial resolution, and
accurate quantification and volumetric localization [97].
Nevertheless, effective resolution of bioluminescence,
fluorescence, or NIR imaging is still suboptimal and the
resulting images are not quantitative, because factors such
as the scattering, attenuation, and dispersion of the emitted
light as it penetrates tissue layers mean the captured signal
is highly dependent on the depth of the tissue of origin
(structures closer to the surface will appear brighter than
deeper structures) [31]. A more recent approach to fluo-
rescence imaging of deeper structures uses fluorescence-
mediated tomography [98], which uses multiple projections
and measures light around the boundaries of the object to
be imaged. After mathematical processing, reconstructed
tomographic images can be obtained with a resolution of
1–2 mm and a fluorochrome detection threshold in the
nanomolar range [32]. In contrast to planar images, these
3D images are quantitative, as the signal intensity is
directly related to the local concentration of fluorochrome
[98].
The photo-acoustic effect was first described by Alex-
ander Bell in 1880, and photo-acoustic tomography (PAT)
was more recently reported by Kruger [99]. It is an imaging
modality that benefits from the advantages of pure OI or
ultrasound imaging, without the major disadvantages of
each technique. This is done by illuminating the sample
with short pulses of laser beams and collecting the ultra-
sound waves generated by the photo-acoustic effect, which
can be described briefly as follows. A fraction of incident
light pulse energy is absorbed by the target tissue and
converted into heat, causing a rise in the temperature and
thus a thermal expansion of the object. This increase in
pressure propagates as a sound wave, which can be
detected externally as an acoustic signal [100]. PAT has
undergone tremendous development in the past decade; in
the near future, its main preclinical applications might
include imaging of angiogenesis, tumor microenviron-
ments, drug response, biomarkers, and gene activity [100].
OI based on high-energy beta particle-emitting radio-
nuclides is the more recently discovered variant of this
imaging modality, described for the first time by Robertson
et al. [101], who showed that positron-emitting (b?) ra-
dionuclides are able to produce visible light, consistent
with Cerenkov radiation, with a continuous spectrum that is
weighted towards the ultraviolet and blue bands of the
electromagnetic spectrum. Cerenkov radiation is produced
when charged particles move at very high speeds, in certain
mediums, allowing the emission of optical photons, which
can be captured by commercially available CCD cameras.
Cerenkov radiation is produced in a continuous spectrum
from the near ultraviolet through the visible spectrum
[101]. Recent works published by Liu et al. [102] and
Robertson et al. [101] demonstrated that, using the low-
energy window of light (1.2–3.1 eV, 400–1,000 nm)
resulting from beta particle-emitting (b? and b-) radio-
nuclides, it is possible to produce images with ordinary OI
equipment. The radionuclide agents that have already been
tested include 18F-FDG, Na18F, Na131I, 90YCl3, and several
90Y-labeled peptides. The advantages of radionuclide OI/
Cerenkov imaging over the conventional OI techniques
essentially relate to the fact that imaging probes are the
same as those used in the clinical context, presenting a
wide emission spectrum, making it possible to monitor the
radioactive probe at different wavelengths with no need for
excitation light. However, some limitations of this tech-
nique, such as limited tissue penetration and relatively poor
quantification ability compared with PET and SPECT are
common to other OI techniques [102]. The first human
‘Cerenkography’ of a patient treated for hyperthyroidism
with 131I was recently (2013) described by Spinelli et al.
[103].
Overall, the most important advantages of OI are the
high sensitivity, low cost, ease of handling, relatively high
throughput, short acquisition time (typically 10–60 sec-
onds), visualization of physiological and pathophysiologi-
cal processes at the cellular and molecular level in vivo
with high specificity, and the possibility of simultaneous
imaging of at least six anesthetized mice [32, 104]. An
additional advantage of OI is the fact that several probes
with different spectral characteristics can be used for
multichannel imaging.
2.9 Ultrasounds
Ultrasounds refer to sound waves with frequencies higher
than 20,000 cycles/s (Hz) that are not detectable by the
human ear [105, 106]. The underlying principle of ultra-
sound imaging resides in the use of the interaction of sound
waves with living tissues/organs to produce images [106].
Diagnostic ultrasound commonly uses frequencies between
2 and 15 MHz [106], while preclinical systems use higher
frequencies (20–50 MHz) to provide images with higher
spatial resolution and an adequate penetration for ana-
tomical and functional real-time information of the animal
models [107].
Ultrasounds offer numerous specialized imaging formats
and techniques that are used routinely in clinical and pre-
clinical practices. Brightness mode (B-mode), motion
mode (M-mode), spectral Doppler and color Doppler are
the most common imaging formats. Ultrasound biomi-
croscopy (UBM), contrast-enhanced imaging, and trans-
esophageal echocardiography (TEE) are three specialized
ultrasound imaging techniques that have been used in
rodents [106]. Doppler-based models are dynamic, real-
time images used to determine the velocity of a moving
tissue and to obtain quantitative structural and functional
information from the target organ [106]. The Doppler
effect is the apparent shift in sound-wave frequency that
occurs when a sound wave is reflected by a moving target,
mainly blood cells. The greater the Doppler shift, the
greater the velocity of the blood flow [106]. Ultrasound
Doppler is widely used in clinical practice to study the
vascular system, namely to determine blood flow velocity
and direction [108] and to image soft tissues.
Contrast agents (material with acoustic properties that
differ from the tissues to be imaged) may be used to
enhance image quality [105]. Molecular-targeted contrast
agents may be used to evaluate biological processes at the
molecular level [109]. The most common ultrasound con-
trast agents are microbubbles, which are small, stabilized
gas-encapsulated microparticles (\10 lm). After
intravenous injection, they behave similarly to the red
blood cells in the circulation, providing a strong reflective
blood/gas interface [110].
Ultrasound biomicroscopy operates at higher frequen-
cies (typically 40–200 MHz) [105, 110] and is able to
acquire images using 2D B-mode, pulsed and continuous
wave Doppler and color flow Doppler [50, 110]. This
imaging modality has been applied in different contexts,
namely the assessment of embryonic and eye development
[111, 112], cardiology [113], and oncology [114].
Ultrasound imaging has several advantages over other
imaging techniques: high spatial and temporal resolution
and a rapid frame rate, allowing real-time and quantitative
imaging; absence of ionizing radiation; low cost; broad
availability; and minimal or no sedation is required [105,
109]. However, ultrasounds can cause bioeffects, including
tissue heating and shock waves [105]. As reproducibility of
the results is highly dependent on the operator, a well
trained and skilled sonographer is required in order to
obtain accurate, repeatable, and high-quality images [106].
Due to limitations in imaging bone and gas-filled struc-
tures, ultrasounds are not commonly used in the brain,
spinal cord, and lung [110].
2.10 Hybrid and Multimodality Imaging
The limitations inherent to each imaging modality, be it
from the technical point of view (low resolution or sensi-
tivity) or applicability (availability of imaging probes), has
driven the widespread combination of two or more
modalities to image the same tissue or organ in the same
animal [30]. Multimodality devices are designed to provide
complementary information upon the subject/pathophy-
siological process being studied. The most common are the
combinations between high sensitivity and functional
modalities, such as PET and SPECT, with high spatial
resolution and morphological techniques, such as CT and
MRI. Multimodal imaging can be achieved either by
acquiring the images in separate devices and performing
image fusion later, using robust software, or acquiring
images almost simultaneously in the same imaging device
with dual- or trimodality. However, software approaches
did not really meet expectations in terms of accuracy of
image registration and fusion or ease of use (since it usu-
ally involves many steps and relies on the operator’s visual
accuracy), making image fusion a difficult task due to
variations in animal positioning. Concerning the second
approach, commercially available systems include the
combination of PET–CT, PET–MRI, SPECT–CT, and,
more recently, SPECT-MRI. Other possible combinations,
such as PET–OI [115], SPECT–OI [116], CT–OI [117],
CT–MRI [118], OI-MRI [119], are also under develop-
ment. It is also possible to find in the market trimodality
systems combining PET–SPECT–CT. Some groups are
working on the development of such additional solutions as
SPECT–CT–OI [120]. Multimodal combination has
enabled some of the most important limitations of each
imaging modality to be overcome when used alone. For
instance, the combination of CT or MRI with PET or
SPECT has allowed more precise localization of focal
points of abnormal tracer uptake, which has contributed to
more accurate diagnosis, in both the clinical and the pre-
clinical setting [121, 122]. In addition, more recently, the
introduction of new technologies, such as avalanche pho-
todiodes (APD) coupled with scintillating crystals (PET or
SPECT), lowered the limits of spatial resolution, improv-
ing the overall image quality while enhancing the overall
sensitivity [123].
CT data can be used to derive a transmission map for
object-specific attenuation correction. Precise attenuation
correction has proven particularly beneficial in the clinical
context [122, 124] as there is an improvement of image
quality paralleled with more accurate quantification.
Attenuation correction is more pertinent in SPECT appli-
cations than in PET, because of its intrinsic dependence on
the unknown depth of the detected photons emanating from
tissues [125]. Synchronous PET–MRI, the only physically
available modality where image acquisition is truly
simultaneous, was initially developed to improve spatial
resolution of PET [126, 127]. In fact, the positron range,
well known to be an intrinsic limiting factor of PET res-
olution, decreases in the presence of strong magnetic fields.
This aspect may be potentially advantageous in preclinical
imaging, particularly when high-energy positron emitters
are used in combination with strong magnetic fields
([4.5 T) [128]. PET–CT and SPECT–CT became com-
mercially available earlier than PET–MRI and have served
as proof of concept that the combination of functional and
morphological imaging techniques could represent more
than the sum of the parts, revealing that PET–MRI and
SPECT–MRI might be equally or even more advantageous,
particularly for brain imaging (Fig. 5). In fact, MRI might
be preferred over CT for a number of reasons: improved
soft tissue contrast (particularly important in neuroimaging
and abdominal and pelvic regions), no additional radiation
exposure (important for longitudinal studies), and the
possibility of obtaining supplementary functional infor-
mation (perfusion, tissue oxygenation, etc.) [129].
In the past, a significant drawback of MRI was the
inability to provide information for attenuation correction.
Nevertheless, due to intense research in the field, several
methods have been presented, while others still under
development are showing very promising results (for a
review, please see Greco et al. [110]). The clinical robust-
ness of these methods is being tested in order to implement
the best of them in the clinical routine in a near future [130].
The combination of PET or SPECT modalities with
MRI has followed a more daring and completely different
approach from that used for CT. The existing systems are
based on the incorporation of PET or SPECT detectors
inside MR magnets, aiming to acquire data at exactly the
same time. Evidently, this has increased the complexity
and presented significant technical challenges (essentially
the electromagnetic interference between the two systems).
A much simpler approach, the combination of nuclear
techniques with CT, is based on a tandem configuration in
which images are acquired sequentially rather than simul-
taneously [129].
Multimodality imaging started with the development of
software tools for image co-registration, followed by ded-
icated instrumentation development. Research has now
been focused on the development of multimodality imag-
ing probes, which are compounds that can provide contrast
for more than one imaging modality (proteins, peptides,
microbubbles, nanoparticles) [129]. Some exciting results
are already being observed in this area, with microbubbles,
traditionally used in ultrasound imaging, the lipid coat of
which might be labeled with fluorescence and/or radionu-
clide agents and thus, used for multimodality imaging
ultrasound–OI–PET/SPECT [131]. Multimodality imaging
of small animals has considerably expanded the type of
information available from a single in vivo experiment,
allowing the visualization of in vivo cellular and metabolic
processes without requiring animal sacrifice.
3 Additional Considerations
The use of animals for research purposes, under strict legal
regulation, requires pre-approval of the physical infra-
structures, the experimental protocols, the imaging devices,
and biosafety and radiation protection procedures. More-
over, specialized and specific staff education and veterinary
support must be assured. The creation of an animal imag-
ing center must be carefully planned, primarily by previ-
ously determining the kind of research that will be held and
which imaging modalities will be needed. The commer-
cially available imaging devices are generally very
expensive, ranging from $US100,000 (for OI systems) to
more than $US2,400,000 (for more sophisticated MRI
systems). Prices will be even higher for multimodality or
hybrid systems. To prevent inefficiencies and unnecessary
increases in overall costs when initiating an imaging
facility, workflow should be optimized. This includes the
determination of which imaging devices to buy, how many,
and their physical localization; which spaces need humid-
ity, temperature, or pressure control (essentially negative or
positive pressurized rooms); what are the special require-
ments concerning the power supply, radiation, and/or
magnetic shielding; biosafety conditions for immunocom-
promised animals; which areas will have restricted or
controlled access; and which spaces need to be supplied
with medical gases. The plan should also include space for
animal husbandry, surgical, and quarantine areas; radio-
chemistry-specific spaces, including a dedicated decay
room; an autoradiography and sectioning room; and a
storage room. It is very important to define the different
flows that may occur in the department (staff, animals,
materials, and radiation sources) in order to avoid cross-
contamination and unnecessary radiation exposure. The
planning and design of an animal imaging facility is a
complex task requiring the expertise of a multi-skilled team
that may include architects, veterinarians, staff from the
provider company (or companies), experienced imaging
technologists, radiopharmacists, physicists, and engineers.
A practical requirement in preclinical imaging is that the
animal remains still during the imaging procedure, which
may often involve the administration of anesthetizing gas
(the most widely used and consensual approach) or
injectable drug cocktails, as well as the use of life- and
comfort-support devices (electrodes and thermometer for
heart rate and temperature monitoring, artificial ventilation,
warming pads, etc.). Ideally, all animal-imaging devices
should be equipped with appropriate immobilization
apparatus, gaseous anesthesia system, barriers for immu-
nocompromised animals, and temperature control. In the
case of rotating gantries, care should be taken in order to
allow the free rotation of the gantry while the animal
remains still in the imaging bed [70]. Moreover, in the case
of longitudinal studies where multiple doses of anesthesia
may be required, the effect of dose and time-interval
between doses should be considered in order to avoid
misleading results.
When choosing the most appropriate imaging modality
(or modalities) for a certain study, one must consider not
only the scientific question to be addressed, but also the
physical conditions and the possible logistic limitations for
the implementation and execution of the experimental
procedures. Data may be more easily transposed to humans
if the chosen modalities for small-animal imaging have
clinical homologs, thus reducing the gap between
Fig. 5 Transverse slices of SPECT and MRI images of a mouse
brain. SPECT was acquired using a specific agent for cortical
benzodiazepine receptors (23I-NNC13-82431). The lack of anatomical
information of SPECT acquisition is complemented with the infor-
mation provided by MRI, in which the eyes, the olfactory bulbs and
the first and second ventricles are shown. The multimodality SPECT-
MRI image provides information about functional benzodiazepine
receptors from SPECT allied to good soft tissue contrast from the
MRI (upper row). Multimodality SPECT-MRI and SPECT-CT
images illustrating the increased soft tissue contrast of MRI modality
compared with CT, emphasizing the added value of adding anatom-
ical information from MRI to function information from SPECT in
the context of brain studies. SPECT images were acquired with 123I-
Iodobenzamide (bottom row). MRI magnetic resonance imaging,
SPECT single photon emission computed tomography
T
a
b
le
6
S
u
m
m
ar
y
o
f
th
e
m
ai
n
ch
ar
ac
te
ri
st
ic
s
o
f
sm
al
l-
an
im
al
im
ag
in
g
m
o
d
al
it
ie
s
Im
ag
in
g
m
o
d
al
it
y
S
p
at
ia
l
re
so
lu
ti
o
n
(m
m
)
S
en
si
ti
v
it
y
D
ep
th
Im
ag
in
g
p
er
io
d
(m
in
)
R
ad
ia
ti
o
n
ex
p
o
si
ti
o
n
(G
y
)
M
ax
im
u
m
n
u
m
b
er
o
f
an
im
al
s/
sa
m
e
st
u
d
y
E
q
u
ip
.
co
st
(M
€)
P
ro
ce
d
u
re
re
la
ti
v
e
co
st
T
y
p
e
o
f
p
ro
b
e
M
aj
o
r
ad
v
an
ta
g
es
M
aj
o
r
li
m
it
at
io
n
s
M
aj
o
r
ap
p
li
ca
ti
o
n
s
S
P
E
C
T
0
.5
–
2
p
M
N
o li
m
it
3
0
–
9
0
0
.1
–
1
.0
4
0
.6
–
0
.8
$
$
V
ar
ie
ty
o
f
m
o
le
cu
le
s
la
b
el
ed
w
it
h
lo
w
-
en
er
g
y
g
am
m
a
em
it
te
rs
L
o
n
g
er
p
h
y
si
ca
l
h
al
f-
li
v
es
;
m
u
lt
ip
le
ra
d
io
n
u
cl
id
es
ca
n
b
e
d
et
ec
te
d
si
m
u
lt
an
eo
u
sl
y
;
p
h
y
si
o
lo
g
ic
al
an
d
m
o
le
cu
la
r
in
fo
rm
at
io
n
L
es
s
se
n
si
ti
v
e
th
an
P
E
T
O
n
co
lo
g
y
;
ca
rd
io
lo
g
y
;
n
eu
ro
lo
g
y
(b
ra
in
p
er
fu
si
o
n
an
d
n
eu
ro
tr
an
sm
is
si
o
n
)
P
E
T
1
–
2
p
M
N
o li
m
it
2
0
–
6
0
0
.1
–
1
.0
4
0
.6
–
0
.8
$
$
$
V
ar
ie
ty
o
f
m
o
le
cu
le
s
la
b
el
ed
w
it
h
p
o
si
tr
o
n
em
it
te
rs
H
ig
h
se
n
si
ti
v
it
y
;
ac
cu
ra
te
q
u
an
ti
fi
ca
ti
o
n
;
d
iv
er
si
ty
o
f
b
io
lo
g
ic
al
p
ro
b
es
av
ai
la
b
le
;
p
h
y
si
o
lo
g
ic
al
an
d
m
o
le
cu
la
r
in
fo
rm
at
io
n
S
h
o
rt
-l
iv
ed
ra
d
io
n
u
cl
id
es
;
im
p
ra
ct
ic
ab
il
it
y
o
f
d
is
tr
ib
u
ti
o
n
o
f
so
m
e
o
f
th
em
;
ex
p
en
si
v
e
eq
u
ip
m
en
t
an
d
o
v
er
al
l
p
ro
ce
d
u
re
O
n
co
lo
g
y
(t
u
m
o
r
m
et
ab
o
li
sm
/
p
ro
li
fe
ra
ti
o
n
,
an
g
io
g
en
es
is
,
h
y
p
o
x
ia
);
n
eu
ro
lo
g
y
C
T
0
.0
5
m
M
N
o li
m
it
1
0
–
1
5
0
.1
–
0
.6
1
0
.2
–
0
.4
$
$
R
ad
io
p
aq
u
e
co
n
tr
as
t
ag
en
ts
S
p
at
ia
l
re
so
lu
ti
o
n
,
p
ar
ti
cu
la
rl
y
fo
r
lu
n
g
an
d
b
o
n
e
im
ag
in
g
;
m
o
rp
h
o
lo
g
ic
al
an
d
p
h
y
si
o
lo
g
ic
al
in
fo
rm
at
io
n
P
o
o
r
so
ft
ti
ss
u
e
co
n
tr
as
t;
ra
d
ia
ti
o
n
ex
p
o
su
re
B
o
n
e,
lu
n
g
s,
v
as
cu
la
r
im
ag
in
g
M
R
I
0
.1
lM
–
m
M
N
o li
m
it
6
0
N
o
n
e
1
0
1
.0
$
$
$
P
ar
am
ag
n
et
ic
m
et
al
ch
el
at
es
/
su
p
er
p
ar
am
ag
n
et
ic
ir
o
n
o
x
id
e
S
p
at
ia
l
re
so
lu
ti
o
n
;
h
ig
h
so
ft
ti
ss
u
e
co
n
tr
as
t;
m
o
rp
h
o
lo
g
ic
al
,
p
h
y
si
o
lo
g
ic
al
an
d
m
o
le
cu
la
r
in
fo
rm
at
io
n
L
o
w
se
n
si
ti
v
it
y
an
d
lo
n
g
ac
q
u
is
it
io
n
ti
m
es
O
n
co
lo
g
y
(t
u
m
o
r
m
et
ab
o
li
sm
an
d
o
x
y
g
en
at
io
n
);
ca
rd
io
lo
g
y
(h
ea
rt
p
er
fu
si
o
n
)
O
I
1
–
2
p
M
–
n
M
m
m
1
–
1
0
N
o
n
e
5
0
.1
–
0
.4
$
F
lu
o
ro
p
h
o
re
s
o
r
b-
em
it
te
rs
H
ig
h
se
n
si
ti
v
it
y
,
h
ig
h
th
ro
u
g
h
p
u
t;
lo
w
co
st
;
p
h
y
si
o
lo
g
ic
al
an
d
m
o
le
cu
la
r
in
fo
rm
at
io
n
L
im
it
ed
d
ep
th
o
f
p
en
et
ra
ti
o
n
O
n
co
lo
g
y
(t
u
m
o
r
an
g
io
g
en
es
is
,
an
d
en
zy
m
at
ic
ac
ti
v
it
y
)
U
S
\
0
.1
–
cm
6
0
N
o
n
e
1
0
.2
–
0
.3
$
M
ic
ro
b
u
b
b
le
s
V
as
cu
la
r
an
d
so
ft
ti
ss
u
e
im
ag
in
g
;
m
o
rp
h
o
lo
g
ic
al
an
d
p
h
y
si
o
lo
g
ic
al
in
fo
rm
at
io
n
D
if
fi
cu
lt
to
im
ag
e
h
o
ll
o
w
o
rg
an
s
an
d
b
o
n
e
V
as
cu
la
r
im
ag
in
g
C
T
co
m
p
u
te
d
to
m
o
g
ra
p
h
y
,
E
q
u
ip
eq
u
ip
m
en
t,
G
y
G
ra
y
,
l
m
m
ic
ro
m
o
la
r,
m
m
m
il
li
m
et
er
,
M
R
I
m
ag
n
et
ic
re
so
n
an
ce
im
ag
in
g
,
M
€
m
il
li
o
n
eu
ro
s,
m
in
m
in
u
te
s,
n
M
n
an
o
m
o
la
r,
O
I
o
p
ti
ca
l
im
ag
in
g
,
P
E
T
p
o
si
tr
o
n
em
is
si
o
n
to
m
o
g
ra
p
h
y
,
p
M
p
ic
o
m
o
la
r,
S
P
E
C
T
si
n
g
le
p
h
o
to
n
em
is
si
o
n
co
m
p
u
te
d
to
m
o
g
ra
p
h
y
,
U
S
u
lt
ra
so
u
n
d
preclinical and clinical studies. In this sense, OI, despite its
low cost and target-specific pharmacodynamics, may not
be a suitable option if direct translation into clinical use is
desired (with the exception of image-guided surgery so
far). Nuclear techniques such as PET and SPECT provide
valuable information at the molecular level about tracer
pharmacokinetics and cellular metabolism. The wide
variety of available molecular probes for nuclear imaging
allows the study of an almost endless number of biological
processes. When choosing PET or SPECT modalities, one
has to consider several aspects such as tracer availability
and related logistics, radionuclide physical half-life, spe-
cific activity of the tracer and the required temporal win-
dow for image acquisition. PET has the highest sensitivity,
allowing more accurate quantification, but SPECT provides
images with higher spatial resolution—it is adequate for
longer studies and is usually less expensive than PET.
Although CT and MRI both provide morphological infor-
mation, each modality may be applied with different pur-
poses: while CT provides maps for attenuation correction
and increased contrast in bone structures, MRI provides
excellent soft tissue contrast and additional functional
information without involving the use of ionizing radiation.
Often, the use of more than one imaging modality may be
required. Although it will necessarily increase the overall
costs, it might provide information that it would otherwise
not be possible to obtain. The most popular combinations
include functional (PET, SPECT) with morphological
imaging modalities (CT, MRI) that provide the anatomical
landmarks of biochemical processes. Table 6 presents a
short overview of the main characteristics of single imag-
ing modalities.
Most often, imaging is only possible through the
administration of intermediates known as imaging probes
(a specific group of biomarkers), which can be simple
molecules such as sodium iodide (I-131) for thyroid scin-
tigraphy or macromolecules, such as labeled peptides as
DOTATOC labeled with Ga-68 for PET imaging of tumors
expressing somatostatin receptors [42]. They should be
able to depict the biochemical processes of interest and to
be detected externally by suitable imaging devices. It is
important that imaging probes should be administered in
tracer amounts so as not to induce pharmacological effects
or interfere with the biological processes under study. The
ideal imaging probe for any specific process should have
the following characteristics: specific uptake by the target
tissue/organ involved in the process being studied, ability
to increase the signal-to-background ratio, ability to accu-
mulate in the target long enough for image acquisition,
presents a simple chemistry, widely available, and low
cost. At the moment, there is no imaging probe with all
these characteristics. However, important efforts are being
made by a huge number of research groups and industrial
entities regarding a broad range of products, with both
diagnostic and therapeutic, or even ‘theranostic’ (so-called
due to the ability to play a role in both fields),
characteristics.
4 Conclusions and Future Trends
Small-animal imaging has driven biomedical research to a
superior level, and are considered high throughput tech-
niques with inherent tremendous advantages over the more
conventional ex vivo techniques, with a clear emphasis on
real-time monitoring, on being non-destructive and non-
invasive, allowing the provision of multiple time points
over a wide timescale (longitudinal studies), and multilevel
information (from cellular and molecular level to organ and
entire organism level), with the additional advantage that
each animal can serve as its own control. In fact, the
development and dissemination of small-animal imaging
equipment and techniques have contributed to a very sig-
nificant reduction in the number of animals required for
scientific research, fully complying with 3R (Replacement,
Reduction and Refinement) polices and strategies. The
most relevant applications are related to new drug dis-
covery and development; target identification; character-
ization of drug pharmacological, pharmacokinetic, and
pharmacodynamic profiles (including safety and validation
studies); and organ function and metabolism in a variety of
pathological contexts. The wide recognition of all those
advantages has driven the increasing use of small-animal
imaging techniques by pharmaceutical companies, contract
research organizations, and research institutions. A recent
report estimates an annual growth rate of the preclinical
imaging market to be about 14.5 % over the next 5 years,
reaching the value of $US1.55 billion dollars in 2017
[132].
Each imaging modality has intrinsic advantages and
limitations, providing different kinds of information, most
often complementary. While nuclear modalities are suited
to providing essentially molecular and functional infor-
mation, CTs and MRIs provide images with superb spatial
resolution. The combination of the so-called functional
with morphological imaging modalities has proven very
advantageous, providing more accurate and useful infor-
mation. PET is by far the most sensitive modality, able to
detect labeled molecules in picomolar concentrations. In
fact, preclinical PET is more often used in the form of
multimodality imaging, occupying first and second place
in the ranking of the most applied combined techniques
with PET–CT and PET–MRI, respectively [50]. The
combination of high-resolution modalities, such as micro-
CT or micro-MRI, with highly sensitive techniques pro-
viding functional information, such as micro-PET or
micro-SPECT, will continue to broaden the horizons of
research in such key areas as infection, oncology, cardi-
ology, and neurology, contributing not only to expanding
the understanding of the underlying mechanisms of dis-
ease, but also to the provision of efficient tools for
evaluating new therapeutic agents. The added value of
multimodality or hybrid imaging approaches has driven
its wide acceptance and widespread application over the
last years. In the near future, hardware and software
levels will further develop, broadening the range of
applications and image quality. Although SPECT is less
sensitive than PET, its radiolabeling chemistry is usually
simpler and easier, including radionuclides with a variety
of photonic energies and half-lives, making possible the
simultaneous acquisition of multiple probes, labeled with
different radionuclides and thus the assessment of distinct
molecular events. Compared with PET, the lower cost and
wider availability of SPECT agents are important aspects
to be considered.
To take full advantage of these techniques, facilities
should be carefully planned in order to optimize workflow,
while always strictly complying with regulatory issues such
as those concerning biosafety, radiation protection, and
animal comfort. Staff should be highly specialized and
specifically trained to work as well and efficiently with the
distinct animal models as with the complexity of the
equipment and devices. In this context, successful teams
are generally multi-skilled, including researchers with
background knowledge as distinct as biology, physiology,
veterinary and animal fare, mathematics, physics, elec-
tronics, imaging processing, radiochemistry, and pharma-
ceutical sciences.
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